DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Lupus Nephritis - Pipeline Review, H2 2016" report to their offering.
Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities
Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Lupus Nephritis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Lupus Nephritis Overview
- Therapeutics Development
- Pipeline Products for Lupus Nephritis - Overview
- Pipeline Products for Lupus Nephritis - Comparative Analysis
- Lupus Nephritis - Therapeutics under Development by Companies
- Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes
- Lupus Nephritis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Lupus Nephritis - Products under Development by Companies
- Lupus Nephritis - Products under Investigation by Universities/Institutes
- Lupus Nephritis - Companies Involved in Therapeutics Development
- AbbVie Inc
- Asahi Kasei Pharma Corp.
- Astellas Pharma Inc.
- Aurinia Pharmaceuticals Inc
- Azano Pharmaceuticals Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Deltanoid Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- HanAll Biopharma Co., Ltd.
- Invion Limited
- KPI Therapeutics, Inc.
- MedImmune, LLC
- Omeros Corporation
- Ra Pharmaceuticals, Inc.
- Resolve Therapeutics, LLC
- Takeda Pharmaceutical Company Limited
- TxCell SA
For more information about this report visit http://www.researchandmarkets.com/research/9xskr9/lupus_nephritis
